Hologic (Hologic) Cash-to-Debt

: 0.75 (As of Dec. 2023)

View and export this data going back to 1990. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Hologic's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.75.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Hologic couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Hologic's Cash-to-Debt or its related term are showing as below:

HOLX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.09 Med: 0.2 Max: 0.97
Current: 0.75

During the past 13 years, Hologic's highest Cash to Debt Ratio was 0.97. The lowest was 0.09. And the median was 0.20.

HOLX's Cash-to-Debt is ranked worse than
67.21% of 863 companies
in the Medical Devices & Instruments industry
Industry Median: 2.01 vs HOLX: 0.75

Hologic Cash-to-Debt Historical Data

The historical data trend for Hologic's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Hologic Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Cash-to-Debt

0.19

0.22

0.37

0.80

0.94

Hologic Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt																0.86	0.91	0.97	0.94	0.75

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Hologic's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hologic Cash-to-Debt Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Hologic's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Hologic's Cash-to-Debt falls into.

Hologic Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Hologic's Cash to Debt Ratio for the fiscal year that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2722.5	/	(310.5	+	2593.6)
	=	0.94

Hologic's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1932.1	/	(40.6	+	2537.4)
	=	0.75

Hologic (NAS:HOLX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Hologic Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Hologic's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Hologic (Hologic) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Hologic Inc (NAS:HOLX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

HOLX:Mexico HO1:Germany HOLX:Austria

Address

250 Campus Drive, Marlborough, MA, USA, 01752

Website

http://www.hologic.com

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (60% of total sales, boosted by pandemic), breast health (14% of sales, suppressed by pandemic), surgical (11%), and skeletal health (1%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

Executives

Charles J Dockendorff	director	COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Scott T Garrett	director	35 CROSBY DRIVE, BEDFORD MA 01730
Stephen P Macmillan	director, officer: President and CEO	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Essex D Mitchell	officer: Div. President, GYN Surgical	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Nanaz Mohtashami	director	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Jennifer M Schneiders	officer: President, Diag. Solutions	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Benjamin Jordan Cohn	officer: Principal Accounting Officer	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Stacey D. Stewart	director	5920 WALHONDING ROAD, BETHESDA MD 20816
Elisabeth A Hellmann	officer: SVP, Human Resources	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Kevin R Thornal	officer: Div. President, Diagnostics	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
John M. Griffin	officer: General Counsel	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Karleen Marie Oberton	officer: Corp. VP, Finance & Acconting	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Erik S Anderson	officer: Div. Pres., Breast & Skeletal	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Jan Verstreken	officer: Group President, International	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Allison P Bebo	officer: SVP, Human Resources	250 CAMPUS DRIVE, MARLBOROUGH MA 01752